The Complete Allergy Care Cycle: From ImmunoCAP ISAC to ROXALL AIT

The complete allergy care cycle, from ImmunoCAP molecular diagnostics to ROXALL allergen immunotherapy (AIT)

The Complete Allergy Care Cycle: From ImmunoCAP to ROXALL AIT

Modern allergology is undergoing a fundamental shift: from symptomatic treatment to disease-modifying therapy that targets the underlying cause. The gold standard of this approach is the complete care cycle, which combines molecular diagnostics based on ImmunoCAP, the international reference technology for specific IgE testing, with allergen immunotherapy (AIT) using ROXALL Medizin products.

KombiMED GmbH is the only company in the region that provides both components of this chain: Thermo Fisher Phadia diagnostic equipment and ROXALL AIT therapeutic products for clinics and laboratories in Kazakhstan, Ukraine, Azerbaijan, Uzbekistan and Kyrgyzstan.

Why Molecular Diagnostics Is a Mandatory Step Before AIT

Allergen immunotherapy (AIT) is the only method that can change the natural course of allergic disease by acting on its cause rather than its symptoms. However, the effectiveness of AIT depends directly on diagnostic accuracy. Classic methods, such as skin prick tests and IgE testing against allergen extracts, cannot distinguish true sensitization from cross-reactivity.

Molecular diagnostics on the ImmunoCAP platform solves this problem by identifying the specific protein components (allergen molecules) to which the patient is sensitized. This makes it possible to:

Distinguish true allergy from cross-reactivity: major proteins (Bet v 1, Der p 1, Phl p 5) indicate genuine sensitization;
Assess the risk of severe systemic reactions: some components (for example, LTP and omega-5 gliadin) are associated with anaphylaxis;
Predict AIT effectiveness: a positive response to a major allergen is a direct predictor of immunotherapy success;
Avoid unnecessary prescriptions: a patient with isolated cross-reactivity does not need AIT.

Step 1. ImmunoCAP ISAC: The Molecular Allergy Profile

ImmunoCAP ISAC (Immuno Solid-phase Allergen Chip) is a multiplex biochip that measures IgE antibodies to 112 allergen components from 51 sources in a single test. The result is a complete molecular profile of the patient's sensitization.

Key benefits for clinicians:

One test instead of dozens: a micro-volume of blood (30 µL) and results from a single assay;
Differentiation of major and minor allergens: precise determination of clinical relevance;
Prediction of AIT effectiveness: identifying major proteins makes it possible to predict the response to immunotherapy;
Detection of polysensitization: comprehensive AIT selection for patients with multiple allergies.

Additional ImmunoCAP Tests

In addition to the ISAC biochip, the ImmunoCAP platform offers a range of targeted tests:

ImmunoCAP Specific IgE: quantitative measurement of IgE to specific allergens (individual extracts and components);
ImmunoCAP Total IgE: total IgE level for assessing atopic status;
ImmunoCAP ECP (Eosinophil Cationic Protein): a marker of eosinophilic inflammation for monitoring asthma and atopic dermatitis;
ImmunoCAP Tryptase: diagnosis of anaphylaxis and mastocytosis.

Step 2. Prescribing AIT Based on the Molecular Profile

With the patient's molecular profile in hand, the allergist can make an informed decision about prescribing AIT:

Positive IgE to a major allergen (Bet v 1 for birch, Phl p 1/p 5 for grasses, Der p 1/p 2 for mites): AIT is indicated and the prognosis is favorable;
IgE only to minor components (PR-10, profilins): cross-reactivity, and AIT is of limited effectiveness;
Polysensitization: identifying the priority allergen with which to start therapy.

Step 3. Treatment with ROXALL AIT Products

ROXALL Medizin (Hamburg, Germany) is a European manufacturer of allergen immunotherapy products. The ROXALL AIT range includes:

SCIT (subcutaneous immunotherapy): injectable products for pollen allergens (trees, grasses, weeds), house dust mites and insect venom;
SLIT (sublingual immunotherapy): drops placed under the tongue, convenient for home use in children and adults;
Custom mixtures: products formulated for the patient's specific sensitization profile.

Advantages of ROXALL AIT

ROXALL Medizin products stand out from the competition:

German quality: manufactured in Hamburg to EU GMP standards;
Broad range of allergens: from tree pollen to insect venom;
Flexible treatment schedules: pre-seasonal, perennial and accelerated (rush) initiation;
Evidence base: clinical studies confirm efficacy and safety.

Why the Complete Cycle Matters for Clinics

Clinics and laboratories that implement the complete "diagnostics + AIT" cycle gain a number of advantages:

Higher quality of care: accurate diagnosis leads to accurate treatment, and patients achieve better outcomes;
Single supplier: one point of contact for equipment, consumables and AIT products simplifies logistics and procurement;
Cost-effectiveness: AIT reduces long-term allergy treatment costs by 60–80%;
Competitive advantage: few clinics in the region offer the complete cycle from molecular diagnostics to AIT.

KombiMED: Exclusive Distributor of ROXALL AIT

KombiMED GmbH (Dortmund, Germany) is the official exclusive distributor of ROXALL Medizin allergen immunotherapy products in five countries:

🇰🇿 Kazakhstan
🇺🇦 Ukraine
🇦🇿 Azerbaijan
🇺🇿 Uzbekistan
🇰🇬 Kyrgyzstan

What We Offer

We provide full-cycle support for allergy services:

Supply of Thermo Fisher Phadia diagnostic equipment (Phadia 250, ImmunoCAP ISAC, consumables);
Supply of ROXALL AIT products (SCIT, SLIT, custom mixtures);
Training for laboratory staff and clinicians;
Technical support and service;
Consulting on the interpretation of molecular diagnostic results.

Conclusion

The complete allergy care cycle, from ImmunoCAP molecular diagnostics to targeted ROXALL AIT therapy, is the gold standard of modern allergology. KombiMED is the only supplier in the region that combines both parts of this chain, giving clinics in Kazakhstan, Ukraine, Azerbaijan, Uzbekistan and Kyrgyzstan access to world-class European technologies.